US Pharma MarketingNovo
The Dutch investment firm has scooped up Novo Nordisk’s head of M&A John McDonald as operating partner of business development and M&A. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Forbion’s portfolio companies have been no stranger to M&A deals in recent years. But the Dutch investment firm now wants more of its biotechs to benefit from the industry’s ...
Source: Endpoints News